Shares surged 10.5% to ₪10,590 on the Tel Aviv Stock Exchange as Teva Pharmaceutical delivered Q2 2026 results that cleared a low bar set by analysts expecting an earnings collapse. Revenue came in at $4.14 billion, down just 1% year-over-year in dollar terms , but comfortably above the consensus estimate of roughly $4.06 billion . The real question: is this a turnaround confirmation or a one-time beat inflated by rock-bottom expectations?
Branded Drugs Are Now Doing the Heavy Lifting
Teva's three flagship branded medicines — its tardive dyskinesia drug, its migraine treatment, and its long-acting schizophrenia injection — collectively grew 43% year-over-year to over $1 billion in quarterly revenue.
Each brand grew at least 40%. That matters because generic product revenue, once Teva's bread and butter, declined — dragged down by lost exclusivity on a key cancer drug. Investors are effectively betting that higher-margin branded drugs can keep compensating for that structural erosion.
The Emalex Acquisition Clouds the Earnings Picture
Teva posted a GAAP net loss of $576 million, largely due to the acquisition of Emalex and its experimental drug ecopipam.
Wall Street had already priced in a roughly 83% EPS decline to just $0.11 , so the beat is relative. Full-year guidance calls for non-GAAP EPS of $1.91–$2.11, which bakes in a $0.66-per-share Emalex-related drag.
Analysts estimate ecopipam could generate $950 million to $1 billion in peak annual sales , but that payoff is years away.
A Credit Upgrade Signals Real Balance Sheet Progress
Fitch raised Teva's corporate credit rating to investment grade (BBB-) during the quarter , a milestone for a company that spent years buried under heavy debt. Yet Teva still faces $1.8 billion in notes maturing in October and $379 million in opioid settlement payments this year , so the balance sheet recovery is ongoing, not complete.
Management Raised the Bar — Now It Has to Clear It
Teva raised its revenue outlook for all three branded drugs based on first-half performance.
Free cash flow guidance holds at $2.0–$2.4 billion , and all 13 covering analysts rate Teva a Buy, with a consensus price target of $41.75 — a 35% premium to the pre-rally U.S. close. The stock's jump today reflects relief, but sustaining it requires proving that branded growth isn't just fast — it's big enough to replace what generics are losing.